Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 511 to 525 of 684 results for kidney or kidneys or renal

  1. HIV testing: encouraging uptake (QS157)

    This quality standard covers interventions to improve the uptake of HIV testing among people who may have undiagnosed HIV. It focuses on increasing testing to reduce undiagnosed infection in people at increased risk of exposure. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    7 September 2017
    View quality statements

    Sections for QS157

  2. Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)

    Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir or Symmetrel) or zanamivir (Relenza) to prevent influenza (flu).

    Technology appraisal guidance
    Published
    24 September 2008
    View recommendations

    Sections for TA158

  3. Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)

    Evidence-based recommendations on amantadine (Lysovir), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza in children and adults.

    Technology appraisal guidance
    Published
    25 February 2009
    View recommendations

    Sections for TA168

  4. Frequency of monitoring: For adults, children and young people with CKD, what is the optimal monitoring frequency for albumin:creatinine ratio?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  5. Frequency of review: What is the most clinical and cost-effective frequency of review for children and young people with CKD?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  6. Renin–angiotensin–aldosterone system antagonists: For people aged over 75 years with CKD, what is the clinical effectiveness of renin–angiotensin–aldosterone system (RAAS) antagonists? [2014]

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  7. Treatment of ESA resistance in people on haemodialysis: What is the most effective type of intervention to treat people on haemodialysis with ESA‑resistant anaemia?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  8. Risk assessment, referral criteria and shared care: What is the association between risk factors and CKD outcomes in children and young people?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  9. Investigations for proteinuria: In children and young people, what is the accuracy of reagent strips for detecting albumin in urine?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  10. Managing anaemia: What are the long-term consequences of high ferritin levels (above 800 micrograms/litre) in children and young people with CKD?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  11. Laparoscopic renal denervation for loin pain haematuria syndrome (IPG709)

    We have moved interventional procedures guidance 709 to become HealthTech guidance 596. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  12. Percutaneous transluminal renal sympathetic denervation for resistant hypertension (IPG754)

    We have moved interventional procedures guidance 754 to become HealthTech guidance 662. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  13. Belzutifan for previously treated advanced renal cell carcinoma [ID6154]

    Discontinued Reference number: GID-TA11086

    Technology appraisal guidance
    Discontinued

  14. Self-management of CKD: Does the provision of educational and supportive interventions to people with CKD by healthcare professionals increase the person's skills and confidence in managing their conditions and improve clinical outcomes?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021

  15. Vitamin D supplements in the management of CKD–mineral and bone disorders: In people with hyperparathyroidism secondary to CKD, does treatment with vitamin D or vitamin D analogues improve patient-related outcomes?

    Source guidance details Comes from guidance Chronic kidney disease: assessment and management Number NG203 Date issued

    Research recommendation
    Published
    30 September 2021